探讨保妇康栓联合重组人干扰素α-2b泡腾片治疗慢性宫颈炎并高危型人乳头瘤病毒感染的临床疗效

Investigation on the Clinical Efficacy of Baofukang Suppository Combined with Recombinant Human Interferonα-2b Effervescent Tablets in the Treatment of Chronic Cervicitis Complicated with High-risk Human Papillomavirus Infection

目的探讨保妇康栓联合重组人干扰素α-2b治疗慢性宫颈炎并高危型人乳头瘤病毒(HPV)感染的临床疗效。方法选取2019年2月—2021年4月该院收治的107例慢性宫颈炎并高危型HPV感染患者,根据治疗方案不同将其分为对照组(n=53)和观察组(n=54),对照组给予重组人干扰素α-2b治疗,观察组给予保妇康栓联合重组人干扰素α-2b治疗。对比两组临床疗效、转阴率、复发率、T淋巴细胞亚群含量。结果观察组总有效率为88.89%,对照组总有效率为71.70%,观察组明显高于对照组,差异有统计学意义(χ^(2)=5.011,P=0.025);观察组转阴率明显高于对照组,复发率明显低于对照组,差异有统计学意义(χ^(2)=4.935、4.881,P=0.026、0.027)。治疗前,两组CD4^(+)、CD8^(+)、CD4^(+)/CD8^(+)比较,差异无统计学意义(t=0.322、0.558、0.635,P=0.748、0.578、0.527);治疗后,两组CD4^(+)、CD8^(+)、CD4^(+)/CD8^(+)均有所上升,且观察组明显高于对照组,差异有统计学意义(t=4.871、16.139、5.100,P<0.001)。结论保妇康栓联合重组人干扰素α-2b治疗慢性宫颈炎并高危型HPV感染,可有效改善临床效果,明显提高转阴率、降低复发率,患者免疫功能显著提高。

Objective To investigate the clinical efficacy of Baofukang suppository combined with recombinant human interferonα-2b in the treatment of chronic cervicitis complicated with high-risk human papillomavirus(HPV)infection.Methods 107 patients with chronic cervicitis and high-risk HPV infection who were admitted to the hospital from February 2019 to April 2021 were selected.According to different treatment plans,they were divided into control group(n=53)and observation group(n=54).The control group was given recombinant human interferonα-2b treatment,and the observation group was given Baofukang suppository combined with recombinant human interferonα-2b treatment.The clinical efficacy,negative conversion rate,recurrence rate,and T lymphocyte subsets were compared between the two groups.Results The total clinical effective rate was 88.89%in the observation group and 71.70%in the control group,the observation group was significantly higher than the control group,and the difference was statistically significant(χ^(2)=5.011,P=0.025).The negative conversion rate of the observation group was significantly higher than that of the control group,and the recurrence rate was significantly lower than that of the control group,and the difference was statistically significant(χ^(2)=4.935,4.881,P=0.026,0.027).Before treatment,there was no statistically significant difference in CD4^(+),CD8^(+),CD4^(+)/CD8^(+) between the two groups(t=0.322,0.558,0.635,P=0.748,0.578,0.527).After treatment,CD4^(+),CD8^(+),CD4^(+)/CD8^(+) in both groups increased,and the observation group was significantly higher than the control group,and the difference was statistically significant(t=4.871,16.139,5.100,P<0.001).Conclusion Baofukang suppository combined with recombinant human interferonα-2b in the treatment of chronic cervicitis complicated with high-risk HPV infection can effectively improve the clinical effect,significantly increase the negative conversion rate,reduce the recurrence rate,and significantly improve the immune function of patients.